RT Journal Article
SR Electronic
T1 Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy
JF Molecular Cancer Therapeutics
JO Mol Cancer Ther
FD American Association for Cancer Research
SP 24
OP 30
DO 10.1158/1535-7163.MCT-06-0443
VO 6
IS 1
A1 Chang, Hong
A1 Schimmer, Aaron D.
YR 2007
UL http://mct.aacrjournals.org/content/6/1/24.abstract
AB Livin, also called melanoma inhibitor of apoptosis protein (IAP) or kidney IAP, is a member of the IAP family of caspase inhibitors that selectively binds the endogenous IAP antagonist SMAC and caspase-3, caspase-7, and caspase-9. As such, Livin inhibits apoptosis, and its overexpression renders malignant cells resistant to chemotherapy. Therefore, inhibitors of Livin could be useful adjuncts to chemotherapy in the treatment of malignancies. This review will discuss Livin as a potential therapeutic target and strategies for its inhibition, including antisense oligonucleotides, small-molecule inhibitors, and immune-mediated approaches. [Mol Cancer Ther 2007;6(1):24–30]